Prolonged rapid eye movement latency may be a potential marker for Alzheimer disease and Alzheimer disease and related dementias.

With the aim to add a “revenue generating CDMO arm,” Lantheus Holdings has bought New Jersey-based radiopharmaceutical ...

Prolonged rapid eye movement sleep latency may be an early indicator of Alzheimer’s disease and related dementias, according ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic ...

Horseheads senior athlete appreciative of support from family, community and medical staff in his battle against cancer.

Instead, patients are often told directly or indirectly that there is “nothing wrong” or that “it’s all in your head.” There is a big difference between a test result that does not reveal an ...

All the experts say socializing, ideally while doing that intellectual activity, can help a lot, because it not only ...

(HealthDay News) — Appropriate use criteria (AUC) for the use of amyloid and tau positron emission tomography (PET) have been issued by the Alzheimer’s Association and the Society for Nuclear Medicine ...

If you have metastatic breast cancer, you may need help from loved ones and your medical team along the way. Here’s how to ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

A 41-year-old man was evaluated for swelling in the ankles and syncope. CT of the chest showed bilateral mediastinal and ...

LNTH Lantheus to Buy Evergreen Theragnostics Lantheus Holdings, Inc. (NASDAQ:LNTH) announced its second acquisition this ...